Risk of valvular heart disease associated with use of fenfluramine

BMC Cardiovascular Disorders

Volumn 3, Issue , 2003, Pages

  Hopkins, Paul N ^a   Polukoff, Gerald I ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Aortic regurgitation; Dexfenfluramine; Fenfluramine; Mitral regurgitation; Risk

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; SEROTONIN RECEPTOR AFFECTING AGENT;

AORTA VALVE REGURGITATION; ARTICLE; CALCULATION; CLASSIFICATION; DATA ANALYSIS; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; ECHOCARDIOGRAPHY; HUMAN; INCIDENCE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; VALVULAR HEART DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; EPIDEMIOLOGY; META ANALYSIS; RISK;

AORTIC VALVE INSUFFICIENCY; BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; DEXFENFLURAMINE; FENFLURAMINE; HUMANS; INCIDENCE; MITRAL VALVE INSUFFICIENCY; PREVALENCE; RISK; SEROTONIN AGENTS;

EID: 0642341479     PISSN: 14712261     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2261-3-5     Document Type: Article

References (34)

1. Connolly HM, Crary JL, McGoon M, Hensrud DD, Edwards BS, Edwards WD and Schaff HV: Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 1997, 337:581-588.
2. Bowen R, Glicklich A, Khan M, Rasmussen S, Wadden T, Bilstad J, Graham D, Green L, Lumpkin M, O'Neill R, Sobel S, Hubbard VS, Yanovski S and Sopko G: Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations. MMWR 1997, 46:1061-1066.
3. Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD and Aber JL: The fen-phen finale: a study of weight loss and valvular heart disease Obes Res 1998, 6:278-284.
4. Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP, Hickey A, Buchbinder NA and Naqvi TZ: Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease Am J Cardiol 2000, 86:107-110.
5. Teramae CY, Connolly HM, Grogan M and Miller F. A., Jr.: Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience Mayo Clin Proc 2000, 75:456-461.
6. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR and Blackburn GL: Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months J Am Coll Cardiol 1999, 34:1153-1158.
7. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW and Vessey JT: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs N Engl J Med 1998, 339:713-718.
8. Weissman NJ, Tighe J. F., Jr., Gottdiener JS and Gwynne JT: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group N Engl J Med 1998, 339:725-732.
9. Shively BK, Roldan CA, Gill EA, Najarian T and Loar SB: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine Circulation 1999, 100:2161-2167.
10. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR and Jensen MD: Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine Mayo Clin Proc 1999, 74:1191-1197.
11. Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P and Glancy DL: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine Obes Res 1999, 7:313-322.
12. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C and Reid CL: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine JAMA 2000, 283:1703-1709.
13. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD and Ryan T: Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities Circulation 2000, 101:2071-2077.
14. Davidoff R, McTiernan A, Constantine G, Davis KD, Balady GJ, Mendes LA, Rudolph RE and Bowen DJ: Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial Arch Intern Med 2001, 161:1429-1436.
15. Palmieri V, Arnett DK, Roman MJ, Liu JE, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Morgan D, de Simone G and Devereux RB: Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study Am J Med 2002, 112:710-715.
16. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS and Derby LE: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation N Engl J Med 1998, 339:719-724.
17. Weissman NJ: Appetite suppressants and valvular heart disease Am J Med Sci 2001, 321:285-291.
18. Loke YK, Derry S and Pritchard-Copley A: Appetite suppressants and valvular heart disease - a systematic review BMC Clin Pharmacol 2002, 2:6.
19. Seghatol FF and Rigolin VH: Appetite suppressants and valvular heart disease Curr Opin Cardiol 2002, 17:486-492.
20. Sachdev M, Miller WC, Ryan T and Jollis JG: Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies Am Heart J 2002, 144:1065-1073.
21. Schiller NB: Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't J Am Coll Cardiol 1999, 34:1159-1162.
22. Khan MA, St. Peter JV and Herzog CA: Appetite-suppressant drugs and valvular heart disease [letter] N Engl J Med 1999, 340:478.
23. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M and Douglas PS: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication Ann Intern Med 1998, 129:870-874.
24. Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD and Reid CL: Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine JAMA 2001, 286:2011-2014.
25. Weissman NJ, Panza JA, Tighe JF and Gwynne JT: Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial Ann Intern Med 2001, 134:267-273.
26. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B and Benjamin EJ: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol 1999, 83:897-902.
27. Reid CL, Gardin JM, Yunis C, T. Kurosaki and Flack JM: Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: The CARDIA Study [abstract] Circulation 1994, 90 (suppl I):I-282.
28. Fleiss JL: Statistical Methods for Rates and Proportions Secondth edition. New York, John Wiley & Sons; 1981.
29. Kleinbaum DG, Kupper LL and Morgenstern H: Epidemiologic Research. Principles and Quantitative Methods. New York, Van Nostrand Reinhold Company, Inc.; 1982.
30. Khan LK, Serdula MK, Bowman BA and Williamson DF: Use of prescription weight loss pills among U.S. adults in 1996-1998 Ann Intern Med 2001, 134:282-286.
31. Moye LA and Annegers AF: Underestimation of the valvulopathy effect of fenfluramine J Am Coll Cardiol 2000, 36:1434-1436.
32. Mast ST, Jollis JG, Ryan T, Anstrom KJ and Crary JL: The progression of fenfluramine-associated valvular heart disease assessed by echocardiography Ann Intern Med 2001, 134:261-266.
33. Volmar KE and Hutchins GM: Aortic and mitral fenfluraminephentermine valvulopathy in 64 patients treated with anorectic agents Arch Pathol Lab Med 2001, 125:1555-1561.
34. Voss LM, Wilson NJ, Neutze JM, Whitlock RM, Ameratunga RV, Cairns LM and Lennon DR: Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial Circulation 2001, 103:401-406.